Evonik Shares Face Crucial First Quarter Assessment

Evonik's Q1 earnings due May 8 show mixed analyst outlooks. Price targets rise despite profit pressure, with methionine markets and energy contracts offering advantages.

As Evonik prepares to release its quarterly figures on May 8, a contradictory picture emerges from the market. While several research firms have recently adjusted their outlooks, their directions are not uniform, creating a landscape of rising price targets alongside declining profit expectations.

Divergent Analyst Views Ahead of Earnings

The consensus market forecast for Evonik's first-quarter earnings before interest, taxes, depreciation, and amortization (EBITDA) sits below the company's own guidance. Evonik management anticipates a result roughly in line with the third quarter of 2025, which saw €448 million. Analysts at Deutsche Bank project a Q1 EBITDA of €461 million, representing an 18% decline compared to the prior-year period, citing pressure from lower margins and negative currency effects.

Nevertheless, Deutsche Bank has raised its price target for the stock from €13 to €15, maintaining a "Hold" rating. In a more bullish move, Goldman Sachs reaffirmed its "Buy" recommendation and increased its target from €18 to €20, basing its call on an EBITDA estimate that exceeds the consensus. Barclays aligns with an "Overweight" stance and a €17 target.

Geopolitical Dynamics and Structural Advantages

Broader market forces are playing an increasingly significant role in the analysis. A Barclays study points to the conflict in the Persian Gulf as a double-edged sword. While chemical producers like Evonik, BASF, and Lanxess could face sector-wide headwinds, Evonik stands to gain notably in the methionine market. Supply constraints are pressuring Asian producers, leading global buyers to seek alternative sources. This dynamic has already driven methionine prices higher in both China and Europe. Consequently, Barclays has lifted its 2026 EBITDA estimate for Evonik to €1.89 billion, 3% above the market consensus.

The company also holds a structural advantage regarding energy costs. Evonik has secured approximately 80% of its energy requirements through long-term contracts, a figure substantially higher than the industry average, providing a buffer against volatility.

Corporate Transformation and Shareholder Returns

The company's "Evonik Tailor Made" transformation initiative remains on schedule. The program aims to achieve annual savings of €400 million by the end of 2026, a process linked to the reduction of up to 2,000 positions globally.

Two key items are slated for discussion at the Annual General Meeting in Essen on June 3. The first is the appointment of a new Chief Financial Officer, a position that has been vacant since September 2025. The second is a vote on the dividend. For 2025, shareholders are set to receive €1.00 per share, down from €1.17 the previous year. Starting in 2026, the payout ratio is expected to be between 40% and 60% of adjusted group net income.

Management reaffirms its full-year 2026 guidance for an adjusted EBITDA ranging from €1.7 to €2.0 billion. The Q1 results on May 8 will provide the first substantive data point to assess the realism of this target range and determine whether the recently elevated analyst price targets are built on a solid foundation.